[go: up one dir, main page]

AR118171A1 - Preparaciones de membrana bacteriana - Google Patents

Preparaciones de membrana bacteriana

Info

Publication number
AR118171A1
AR118171A1 ARP200100496A ARP200100496A AR118171A1 AR 118171 A1 AR118171 A1 AR 118171A1 AR P200100496 A ARP200100496 A AR P200100496A AR P200100496 A ARP200100496 A AR P200100496A AR 118171 A1 AR118171 A1 AR 118171A1
Authority
AR
Argentina
Prior art keywords
membrane preparations
bacterial membrane
bacterial
preparations
useful
Prior art date
Application number
ARP200100496A
Other languages
English (en)
Inventor
Erin B Troy
Baundauna Bose
Brian Goodman
Original Assignee
Evelo Biosciences Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Evelo Biosciences Inc filed Critical Evelo Biosciences Inc
Publication of AR118171A1 publication Critical patent/AR118171A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/74—Bacteria
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/05—Actinobacteria, e.g. Actinomyces, Streptomyces, Nocardia, Bifidobacterium, Gardnerella, Corynebacterium; Propionibacterium
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/095—Neisseria
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/10—Cellular immunotherapy characterised by the cell type used
    • A61K40/11—T-cells, e.g. tumour infiltrating lymphocytes [TIL] or regulatory T [Treg] cells; Lymphokine-activated killer [LAK] cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/10—Cellular immunotherapy characterised by the cell type used
    • A61K40/19—Dendritic cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/20—Cellular immunotherapy characterised by the effect or the function of the cells
    • A61K40/24—Antigen-presenting cells [APC]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/30—Cellular immunotherapy characterised by the recombinant expression of specific molecules in the cells of the immune system
    • A61K40/31—Chimeric antigen receptors [CAR]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/41—Vertebrate antigens
    • A61K40/42—Cancer antigens
    • A61K40/4201—Neoantigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N1/00—Microorganisms, e.g. protozoa; Compositions thereof; Processes of propagating, maintaining or preserving microorganisms or compositions thereof; Processes of preparing or isolating a composition containing a microorganism; Culture media therefor
    • C12N1/20—Bacteria; Culture media therefor
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/01—Preparation of mutants without inserting foreign genetic material therein; Screening processes therefor
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
    • C12P1/00—Preparation of compounds or compositions, not provided for in groups C12P3/00 - C12P39/00, by using microorganisms or enzymes
    • C12P1/04—Preparation of compounds or compositions, not provided for in groups C12P3/00 - C12P39/00, by using microorganisms or enzymes by using bacteria
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55566—Emulsions, e.g. Freund's adjuvant, MF59
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
    • A61K2039/6031—Proteins
    • A61K2039/6081—Albumin; Keyhole limpet haemocyanin [KLH]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K40/00
    • A61K2239/46—Indexing codes associated with cellular immunotherapy of group A61K40/00 characterised by the cancer treated
    • A61K2239/50—Colon
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Genetics & Genomics (AREA)
  • Microbiology (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Mycology (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Diabetes (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • Rheumatology (AREA)
  • Obesity (AREA)
  • Virology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Transplantation (AREA)
  • Physics & Mathematics (AREA)
  • Endocrinology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Dermatology (AREA)
  • Pain & Pain Management (AREA)

Abstract

Se proporcionan en el presente documento métodos y composiciones relacionadas con preparaciones de membrana (MP) útiles como agentes terapéuticos.
ARP200100496A 2019-02-22 2020-02-21 Preparaciones de membrana bacteriana AR118171A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201962809292P 2019-02-22 2019-02-22

Publications (1)

Publication Number Publication Date
AR118171A1 true AR118171A1 (es) 2021-09-22

Family

ID=70005742

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP200100496A AR118171A1 (es) 2019-02-22 2020-02-21 Preparaciones de membrana bacteriana

Country Status (13)

Country Link
US (1) US20220118030A1 (es)
EP (1) EP3927356A2 (es)
JP (1) JP2022520999A (es)
KR (1) KR20210133986A (es)
CN (1) CN113727722A (es)
AR (1) AR118171A1 (es)
AU (1) AU2020225473A1 (es)
BR (1) BR112021016605A2 (es)
CA (1) CA3130776A1 (es)
CO (1) CO2021012176A2 (es)
MX (1) MX2021010160A (es)
TW (1) TW202045192A (es)
WO (1) WO2020172492A2 (es)

Families Citing this family (45)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN111518781B (zh) * 2019-07-31 2022-02-15 江南大学 一种谷氨酰胺转氨酶复合酶及其在人造肉加工中的应用
EP4038192A4 (en) 2019-10-01 2023-11-01 Empyrean Neuroscience, Inc. GENETIC ENGINEERING MUSHROOMS TO MODULATE TRYPTAMINE EXPRESSION
US20240066074A1 (en) * 2020-09-11 2024-02-29 California Institute Of Technology Probiotic treatments for parkinson's disease
WO2022098961A1 (en) * 2020-11-06 2022-05-12 Evelo Biosciences, Inc. Inducing immune effects using veillonella parvula bacteria
TW202237155A (zh) * 2020-12-14 2022-10-01 美商艾弗洛生物科技股份有限公司 細胞外囊泡製劑
US20240423924A1 (en) * 2021-01-26 2024-12-26 Evelo Biosciences, Inc. Prevotella extracellular vesicle preparations
MX2023008874A (es) * 2021-01-29 2023-08-15 Zivo Bioscience Inc Maduracion de procesos inmunitarios y metabolicos a traves de biomasa de algas y/o material relacionado administrado a animales.
CN112899188A (zh) * 2021-01-29 2021-06-04 西南大学 一种促进作物根系发育的微生物菌剂及其制备与应用
TW202302125A (zh) * 2021-03-05 2023-01-16 美商艾弗洛生物科技股份有限公司 固體劑型
KR102582570B1 (ko) * 2021-03-19 2023-09-22 한국생명공학연구원 유박테리움 칼란데리, 이의 배양액 또는 이의 배양액 추출물을 유효성분으로 포함하는 암 예방 또는 치료용 조성물
CN115305211A (zh) * 2021-05-07 2022-11-08 葡萄王生技股份有限公司 益生菌胞外泌体及其用途
US20240277005A1 (en) * 2021-06-30 2024-08-22 Kiverdi, Inc. Reduction of endotoxins in bacterial protein preparations
JP2024527078A (ja) * 2021-07-28 2024-07-19 ザ テキサス エーアンドエム ユニヴァーシティ システム ブルセラ属株を含むワクチン組成物及びそれらの方法
KR102881730B1 (ko) * 2021-10-20 2025-11-06 주식회사 고바이오랩 항암 활성을 갖는 신규 박테리아 균주 및 이를 이용한 암의 완화, 예방 또는 치료용 조성물
CN114085875B (zh) * 2021-11-10 2023-04-25 四川大学 一种胞外多糖、制备方法及其应用
WO2023107583A1 (en) * 2021-12-07 2023-06-15 Zivo Bioscience, Inc. Brevundimonas sp for use in disease prevention and treatment
CN114410503B (zh) * 2021-12-08 2023-10-03 中南大学 一种锰氧化菌及其筛选方法和应用
WO2023114295A1 (en) * 2021-12-14 2023-06-22 Evelo Biosciences, Inc. Veillonella parvula bacteria extracellular vesicle preparations
WO2023130076A2 (en) 2021-12-31 2023-07-06 Empyrean Neuroscience, Inc. Targets and pathways for the production of alkaloidal compounds
TWI819483B (zh) * 2022-01-28 2023-10-21 加捷生醫股份有限公司 乳酸菌組成物及其用於製備抑制抗藥性腸桿菌之口服組成物的用途
CN116732117B (zh) * 2022-03-01 2025-11-18 中国医学科学院医药生物技术研究所 Hungatella属菌株在对黄酮碳苷进行生物转化中的应用
CN114262683B (zh) * 2022-03-01 2022-06-17 中国科学院动物研究所 一种表达vegfr3 d2多肽的细菌制剂及其构建方法和应用
CA3247168A1 (en) * 2022-04-05 2023-10-12 Mybiotics Pharma Ltd. BACTERIAL COMPOSITIONS AND METHODS OF CULTURE BACTERIA ON PARTICLES
WO2023215869A2 (en) * 2022-05-06 2023-11-09 Biological Mimetics, Inc. Inactivated staphylococcus compositions and methods of making and using the same
KR102551061B1 (ko) * 2022-05-26 2023-07-03 중앙대학교 산학협력단 Saha를 유효성분으로 포함하는 살모넬라 속 균주에 의한 바이오필름 생성 저해용 조성물
WO2023239728A1 (en) * 2022-06-07 2023-12-14 Evelo Biosciences, Inc. Compositions and methods of treating inflammation using prevotella histicola extracellular vesicles
KR102509869B1 (ko) * 2022-07-14 2023-03-14 주식회사 엔테로바이옴 아커만시아를 포함하는 탈모 예방 또는 치료용 약학적 조성물
CN115607573B (zh) * 2022-12-16 2023-05-23 北京大学第三医院（北京大学第三临床医学院） 一种用于调节杀伤性t细胞活性的方法、药物及其应用
CN116236610A (zh) * 2022-12-28 2023-06-09 四川大学 一种多酚修饰zif装载活性分子的丝素蛋白和明胶复合支架及其制备方法和用途
KR102555748B1 (ko) * 2023-03-23 2023-07-17 주식회사 그린스토어 항균, 항진균, 항염 활성 및 치아 우식 억제 활성을 갖는 신규한 스트렙토코커스 살리바리우스 균주 kccm13161p 및 이를 포함하는 구강용 조성물
CN117106611A (zh) * 2023-03-29 2023-11-24 湖北省烟草公司恩施州公司 一株内生耐冷草假单胞菌菌株eh7及其应用
CN116355811B (zh) * 2023-04-26 2025-03-18 南京农业大学 一种食淀粉乳杆菌及其在改善胆汁淤积性肝病中的应用
CN116212091B (zh) * 2023-05-09 2023-08-01 天津包钢稀土研究院有限责任公司 一种复合抗菌剂、人体友好型医用抗菌敷料及其制备方法
WO2024259003A1 (en) * 2023-06-12 2024-12-19 The Board Of Trustees Of The Leland Stanford Junior University Systems and methods for assessment of microbiome and treatments thereof
CN116794313B (zh) * 2023-08-18 2023-11-03 江西赛基生物技术有限公司 基于流式细胞仪同时检测三项肿瘤标志物的试剂盒及方法
CN117683654B (zh) * 2023-10-11 2024-08-13 青岛大学附属医院 一种产尿酸氧化酶的菌株44xb及其应用
KR20250063871A (ko) * 2023-10-27 2025-05-09 주식회사 노드큐어 락토바실러스 사케이(Lactobacillus sakei) CVL-001 또는 락토바실러스 루테리(Lactobacillus reuteri) NCHBL-005를 포함하는 항결핵제 유도 약물 독성 완화용 병용 투여 제제, 및 이를 포함하는 결핵 예방 또는 치료용 약제학적 조성물
EP4548928A1 (en) 2023-10-31 2025-05-07 Institut de Recerca i Tecnologia Agroalimentaries (IRTA) Rothia nasimurium or immunomodulatory fraction thereof in the prevention and/or treatment of an infection or a non-infectious disease in a subject
CN117264850B (zh) * 2023-11-09 2024-05-14 潍坊君薇生物科技有限责任公司 一种具有辅助治疗阴道炎和增强免疫力功能的戊糖片球菌sw006及其应用
CN117264854B (zh) * 2023-11-17 2024-01-26 云南农业大学 一种植物乳杆菌及其应用
CN117402794B (zh) * 2023-12-12 2024-02-27 四川厌氧生物科技有限责任公司 一种加氏乳杆菌及其应用
CN117603884B (zh) * 2024-01-17 2024-03-26 广州同康生物科技有限公司 一种嗜黏蛋白阿克曼氏菌菌粉及其制备方法
CN118995541B (zh) * 2024-10-24 2025-01-24 青岛诺和诺康生物科技有限公司 乳酸片球菌及其改善脑卒中、脂肪肝及尿酸代谢的应用
CN119351282B (zh) * 2024-12-24 2025-10-28 中国疾病预防控制中心传染病预防控制所 单形拟杆菌CGMCC No.30981在制备哮喘治疗药物中的应用
CN120330113B (zh) * 2025-06-23 2025-09-16 上海菌济健康科技有限公司 具有尿酸降解及护肾作用的乳酸片球菌pa3-7及其应用

Family Cites Families (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2444464A1 (fr) * 1978-12-19 1980-07-18 Fabre Sa Pierre Proteoglycanes bacteriens purifies, procede pour leur preparation et vaccin les contenant
FR2523154A1 (fr) * 1982-03-09 1983-09-16 Fabre Sa Pierre Procede de preparation de proteoglycanes immunostimulants inducteurs d'interferon, proteoglycanes obtenus et medicaments les contenant
US4581226A (en) * 1983-04-07 1986-04-08 Dillon Richard S Method of treating sensitive animal tissue with a specially processed seawater solution
DE19703437A1 (de) * 1997-01-30 1998-08-06 Luitpold Pharma Gmbh Gemische äußerer Membranen und/oder Zellwände von Bakterien zur oralen Immunisierung gegen Schleimhautinfektionen
EP2261338A3 (en) * 1998-05-01 2012-01-04 Novartis Vaccines and Diagnostics, Inc. Neisseria meningitidis antigens and compositions
FR2790960B1 (fr) * 1999-03-15 2002-10-31 Pf Medicament Utilisation de fractions membranaires bacteriennes a activite immunostimulante dans le traitement de cancers, leurs procedes de preparation et les compositions pharmaceutiques les contenant
FR2790959B1 (fr) * 1999-03-15 2003-06-27 Pf Medicament Utilisation de fractions membranaires bacteriennes a effet adjuvant, leurs procedes de preparation et composition pharmaceutique les contenant
FR2822071B1 (fr) * 2001-03-15 2005-07-01 Pf Medicament Utilisation d'une fraction membranaire de bacteries a gram negatif pour induire la maturation des cellules dendritiques
GB0220194D0 (en) * 2002-08-30 2002-10-09 Chiron Spa Improved vesicles
NL1022153C2 (nl) * 2002-12-12 2004-06-15 Tno Cholesterol verlagend preparaat, voedingssupplement en voedingsmiddel en werkwijzen voor de bereiding daarvan.
GB0424092D0 (en) * 2004-10-29 2004-12-01 Chiron Srl Immunogenic bacterial vesicles with outer membrane proteins
US20100166840A1 (en) * 2006-05-12 2010-07-01 Japan Bcg Laboratory Liposome having lipid membrane containing bacterial cell component
EP2424550B1 (en) * 2009-04-29 2017-06-07 Ganeden Biotech, Inc. Bacterial cell membrane formulation
TR201808206T4 (tr) * 2011-07-07 2018-07-23 De Staat Der Nederlanden Vert Door De Mini Van Vws Bir gram negatif bakterinin dış membran veziküllerinin deterjan içermeyen üretimi prosesi.
MX363529B (es) * 2012-09-18 2019-03-27 Novartis Ag Vesículas de membrana externa.
AU2015240884B2 (en) * 2014-03-31 2020-06-18 Biomed Valley Discoveries, Inc. Use of bacteria, bacterial products, and other immunoregulatory entities in combination with anti-CTLA-4 and/or anti-PD-1 antibodies to treat solid tumor malignancies
JP2018515426A (ja) * 2015-03-12 2018-06-14 ザ ユニヴァーシティ オブ ブリティッシュ コロンビア 細菌組成物およびその使用方法
GB201514302D0 (en) * 2015-07-16 2015-09-23 Dupont Nutrition Biosci Aps Lactobacilli for treating cardiac dysfunction
ES2979112T3 (es) * 2016-04-14 2024-09-24 Int N&H Denmark Aps Bifidobacterias para reducir la ingesta de alimentos, energía y/o grasas
JP2020533291A (ja) * 2017-09-08 2020-11-19 エヴェロ バイオサイエンシズ，インコーポレーテッド プレボテラ（Ｐｒｅｖｏｔｅｌｌａ）由来の細胞外小胞
AU2018330322A1 (en) * 2017-09-08 2020-03-19 Evelo Biosciences, Inc. Bacterial extracellular vesicles
WO2019157003A1 (en) * 2018-02-06 2019-08-15 Evelo Biosciences, Inc. Compositions and methods for treating cancer and immune disorders using veillonella bacteria
WO2020006216A1 (en) * 2018-06-27 2020-01-02 Evelo Biosciences, Inc. Compositions and methods of treating cancer using neisseria bacteria

Also Published As

Publication number Publication date
CA3130776A1 (en) 2020-08-27
MX2021010160A (es) 2021-09-14
KR20210133986A (ko) 2021-11-08
WO2020172492A3 (en) 2020-10-08
CN113727722A (zh) 2021-11-30
EP3927356A2 (en) 2021-12-29
JP2022520999A (ja) 2022-04-04
TW202045192A (zh) 2020-12-16
AU2020225473A1 (en) 2021-09-30
BR112021016605A2 (pt) 2022-01-18
CO2021012176A2 (es) 2021-09-30
US20220118030A1 (en) 2022-04-21
WO2020172492A2 (en) 2020-08-27

Similar Documents

Publication Publication Date Title
CO2021012176A2 (es) Preparaciones de membrana bacteriana
CO2022000040A2 (es) Vesículas extracelulares microbianas procesadas
CO2020004233A2 (es) Vesículas extracelulares bacterianas
CO2020010956A2 (es) Composiciones y métodos para el tratamiento del cáncer y de trastornos inmunitarios usando bacterias de veillonella
CO2020007142A2 (es) Composiciones y métodos para el tratamiento de los trastornos inmunitarios utilizando cepas de bacterias inmunomoduladoras de lactococcus
MX2020002660A (es) Vesiculas extracelulares de prevotella.
ECSP20004580A (es) Moduladores de moléculas pequeñas de sting humana
CL2019002135A1 (es) Células microbianas, métodos para producir las mismas, y usos de las mismas.
MX384128B (es) Composiciones y metabolitos bioactivos de bacillus megaterium.
EP4620521A3 (en) Methods and compositions relating to chondrisomes from cultured cells
CL2020001442A1 (es) Conjugados anticuerpo anti-cd40-fármaco.
CO2020016678A2 (es) Tiofenocarboxamidas sustituidas y análogos como agentes antibacterianos
CO2022002066A2 (es) Métodos y composiciones para cultivar bacterias dependientes de hemoglobina
MX389490B (es) Peptidos y su uso en el tratamiento de la piel.
CO2020016131A2 (es) Agonistas de tlr7
AR115359A1 (es) Preparaciones microbianas para plantas, composiciones y formulaciones que las comprenden y sus usos
MX2020013389A (es) Composiciones de terlipresina y usos de las mismas.
CO2023000114A2 (es) Composiciones y métodos para el tratamiento de enfermedades y trastornos usando vesículas extracelulares microbianas de oscillospiraceae
DOP2019000102A (es) Constructos de vacuna y sus usos contra infecciones causadas por staphylococcus
MX2017005163A (es) Composiciones de liberación prolongada de onapristona y métodos.
CO2021016916A2 (es) Métodos y composiciones para la fermentación bacteriana anaerobia
CL2018002368A1 (es) Formulaciones de oritavancina
CO2020001506A2 (es) Nuevos compuestos
MX2024003981A (es) Composiciones para iluminar y metodos de uso.
AR120058A1 (es) Vesículas extracelulares microbianas procesadas

Legal Events

Date Code Title Description
FA Abandonment or withdrawal